Guselkumab Efficacious for Moderately to Severely Active Crohn Disease in Adults

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 24, 2025.

via HealthDay

THURSDAY, July 24, 2025 -- Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately to severely active Crohn disease, according to a study published online July 17 in The Lancet.

Remo Panaccione, M.D., from the University of Calgary in Alberta, Canada, and colleagues examined the efficacy and safety of intravenous induction followed by subcutaneous maintenance therapy with guselkumab over 48 weeks in adults with moderately to severely active Crohn disease based on results from two phase 3 trials (GALAXI-2 [508 participants] and GALAXI-3 [513 participants]). Adults with moderately to severely active Crohn disease were enrolled at 257 sites across 40 countries and assigned to guselkumab 200 mg, guselkumab 100 mg, ustekinumab, or placebo.

The researchers found that compared with placebo, both guselkumab regimens were superior for the coprimary composite end point of clinical response at week 12 and clinical remission at week 48 in GALAXI-2 (adjusted treatment difference, 43 and 38 percent in the guselkumab 200-mg and 100-mg groups, respectively) and in GALAXI-3 (corresponding adjusted treatment difference, 35 and 34 percent, respectively). Compared with placebo, both guselkumab regimens were superior for the coprimary composite end point of clinical response at week 12 and endoscopic response at week 48 in GALAXI-2 (adjusted treatment difference, 33 and 34 percent, respectively) and in GALAXI-3 (adjusted treatment difference, 31 and 28 percent, respectively).

"Patients receiving guselkumab showed significantly higher rates of endoscopic healing and deep remission, critical indicators linked to fewer disease flares, hospitalizations, and long-term complications," senior author Bruce E. Sands, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, said in a statement.

Several authors disclosed ties to biopharmaceutical companies, including Johnson & Johnson, which manufactures guselkumab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords